Fig. 7: TRIM21-METTL3 axis promotes the therapeutic efficacy of PD-1 antibodies. | Cell Death & Disease

Fig. 7: TRIM21-METTL3 axis promotes the therapeutic efficacy of PD-1 antibodies.

From: TRIM21-mediated METTL3 degradation promotes PDAC ferroptosis and enhances the efficacy of Anti-PD-1 immunotherapy

Fig. 7

A Schematic showing the treatment schedule to evaluate anti–mPD-1 treatment in different groups. B Tumors were dissected and photographed. C Differences in tumor volume in response to different treatments (n = 5). D, E IF staining and quantification showing the expression of PD-L1 in different groups. Scale bar, 50 µm. F Flow cytometry analysis exhibiting the proportions of infiltrating CD4+ and CD8+ cells in tumor tissues in response to different groups. G, H Granzyme B and IFN-γ expression in CD8+ T cells from anti PD-1–treated tumors. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns not significant).

Back to article page